HusseinAbbasMDPhD

Hematologic Oncology

Physician

Dr. Abbas is on Doximity

As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.

Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
Connect with colleagues in the same hospital or clinic.
Read the latest clinical news, personalized to your specialty.

University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2018 - 2021
University of Texas Health Science Center at Houston/M D Anderson Cancer CenterFellowship, Hematology and Medical Oncology, 2021
University of Texas M.D. Anderson Cancer CenterOncology, 2021
Johns Hopkins UniversityResidency, Internal Medicine, 2016 - 2018
University of Texas M.D. Anderson Cancer CenterPost-Doctoral Fellowship, 2014 - 2016
American University of Beirut Faculty of MedicineClass of 2014, MD
University of Texas M D Anderson Cancer CenterPhD, Cancer Biology and Genes & Development, Floyd Haar Endowed Memorial Research Award, William A. and Madelyn Welder Smith Foundation Fellowship, 2006 - 2010
Lebanese American UniversityBS, Biology, High distinction, 2003 - 2006

T32 NIH Trainee Grant Research in Medical Oncology NIH - MD Anderson Cancer Center
Kimberly Patterson Fellowship In Leukemia Research M D Anderson Cancer Center, 2020
Young Investigator Award Adaptive Biotechnologies, 2018-2019
Odyssey Scholar M D Anderson Cancer Center, 2014-2016
William A. and Madelyn Welder Smith Foundation Fellowship University of Texas Health Science Center, 2009
Best Poster Award Gordon Research Conference, 2009
Floyd Haar Endowed Memorial Research Award University of Texas Health Science Center, 2009
Student's Honor Society Lebanese American University, 2003-2006
High Distinction Recognition Lebanese American University, 2003-2006
Join now to see all

PubMed

Clinical interrogation of TP53 aberrations and its impact on survival in patients with myeloid neoplasms.
Jayastu Senapati, Sanam Loghavi, Guillermo Garcia-Manero, Guillin Tang, Tapan Kadia
Haematologica. 2024-12-12
Impact of Measurable Residual Disease Clearance Kinetics in Patients with AML Undergoing Intensive Chemotherapy.
Wei Ying Jen, Koji Sasaki, Farhad Ravandi, Tapan M Kadia, Sa A Wang
Blood Advances. 2024-12-04
Outcomes of Patients With Newly Diagnosed AML and Hyperleukocytosis.
Fadi G Haddad, Koji Sasaki, Jayastu Senapati, Lianchun Xiao, Grace Park
JCO Oncology Practice. 2024-12-01

Abstracts/Posters

Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo + Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
Hussein Abbas, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019

Lectures

IL2-STAT5 immune signatures to predict responses to PD-1 inhibition and azacitidine treatment in acute myeloid leukemia (AML): A subset analysis of a phase 2 study.
2019 ASCO Annual Meeting - 6/1/2019

MD Anderson Researchers Receive Over $25.5 Million in CPRIT FundingFebruary 23rd, 2024
Why More Clinical Labs Are Turning to Whole-Genome Sequencing for CancerApril 6th, 2024